Health News Releases

  • Today May 17
December 16, 2019 10:29
PCI Pharma Services Announces Major Investment to Expand Development and Manufacturing Capabilities at Tredegar, UK Site
PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced it has begun an expansion of its Tredegar facility in Wales, UK to enha
December 13, 2019 13:47
OncoSec CEO Sends Letter to Fellow Shareholders
Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today sent t
December 12, 2019 15:51
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 tri
December 11, 2019 17:03
Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019
Octapharma has announced today that the final results from the NuProtect study, the largest prospective study of a single factor VIII (FVIII) product in true PUPs with severe haemophilia A, were prese
December 11, 2019 16:13
Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho
Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it has entered into an exclusive license agreement with Maruho
December 10, 2019 23:50
Panda Biotech Plans the Largest Industrial Hemp Processing Facility for Fiber and Cellulose in the United States
Dallas-based Panda Biotech today announced it is developing its first industrial hemp processing facility to produce high-quality, textile-grade fiber and premium cellulose. The “Panda High Plains Hem
December 10, 2019 17:13
PanTheryx Bovine Colostrum Recognized as GRAS
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies to address a wide range of health conditions, today announced that an independent expert pan
December 10, 2019 17:04
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that undersc
December 10, 2019 11:45
OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Execut
December 09, 2019 17:47
Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associat
December 09, 2019 14:31
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (
December 06, 2019 11:06
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme
December 05, 2019 12:22
Macrogen Research Outcome from ‘GenomeAsia 100K’ Covered in Nature
The precision medicine and biotechnology company Macrogen (Chairman Jung-Sun Seo, www.macrogen.com) (KOSDAQ: 038290) announced on Dec 5 that the result of its Asian genome analysis, which has been per
December 03, 2019 11:13
Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019
Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner (Great Ormond Street Hospital for Children, London, UK) as an oral presentation at the 61st An
December 03, 2019 10:24
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
OncoSec Medical Incorporated (NASDAQ: ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. The fu
November 27, 2019 11:14
GN CORPORATION: Vision Restored with Corneal Cell Transplant Using a Nano Sheet Technique; Japanese Firm Granted Patent in India
A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian patent to GN
November 26, 2019 17:08
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) today announced that updated results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TID
November 26, 2019 11:48
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lym
November 26, 2019 10:09
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patien
November 26, 2019 09:11
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in
November 25, 2019 13:44
Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients
Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient S
November 22, 2019 11:21
PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies, today announced a multimillion dollar agreement between its wholly-owned subsidiary APS Bio
November 18, 2019 14:00
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding
November 18, 2019 10:41
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas
November 15, 2019 11:37
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strat
25 per page50 per page75 per page100 per page